Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
A phase 3 trial of Fulvestrant, Gedatolisib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Celcuity Inc, now recruiting.
Overview
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) is a phase 3 interventional study registered as NCT06757634 by Celcuity Inc, with 1180 participants planned, started 2025-07-24 and due to reach its primary completion in 2029-03-31. Interventions recorded: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole and Arm D: Ribociclib + Letrozole.
Similar pages
not linked directly; found by shared links- TrialGedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Shares Celcuity, Gedatolisib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Ribociclib, Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Shares Ribociclib, Palbociclib, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Ribociclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Shares Ribociclib, Palbociclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Ribociclib, Palbociclib, Fulvestrant and the tag pipeline.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Palbociclib, Fulvestrant and the tag pipeline.